Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
227 Results Found
CMS opens comment period for Medicare Drug Price Negotiation Program
The Centers for Medicare & Medicaid Services May 3 announced the opening of the comment period for the Inflation Reduction Act’s Medicare Drug Price Negotiation Program, which will negotiate prices with drug makers for certain high-cost, sole-source drugs and apply them beginning in 2026. Comments are due July 2.
White House official spotlights the Administration’s efforts on coverage, drug prices, health care workforce
White House Domestic Policy Council Director Neera Tanden spoke to Annual Meeting attendees about the environment hospitals and health systems are facing and the Biden Harris Administration’s efforts to strengthen the health care system so that it works for everyone.
FTC, HHS seek comment on generic drug shortages and competition
The Federal Trade Commission and Department of Health and Human Services Feb. 14 requested comments for 60 days on market concentration and contracting practices among group purchasing organizations and drug wholesalers to understand their potential impact on pricing and generic drug shortages.
President proposes congressional, federal action to lower drug costs
President Biden urged Congress to allow Medicare to negotiate prescription drug prices and cap the amount beneficiaries pay out-of-pocket for drugs each year.
Administration actions target health care competition, lower drug costs
The Department of Health and Human Services, Department of Justice, and Federal Trade Commission Dec. 7 announced several new actions to promote competition in health care and support lower prescription drug costs.
CMS: Makers of selected drugs agree to participate in Medicare price negotiation
The companies that make the first 10 Medicare Part D drugs selected to participate in the Medicare Drug Price Negotiation Program have agreed to participate in the program’s price negotiations, the Centers for Medicare & Medicaid Services announced.
FDA seeks comments on updated labeling guidance for biosimilar products
The Food and Drug Administration will accept comments through Nov. 17 on draft guidance for labeling proposed biosimilar and interchangeable biosimilar products.
CMS releases fact sheet on Medicare drug price negotiation process
A new Centers for Medicare & Medicaid Services fact sheet reviews how the agency selected the first 10 Part D drugs to include in the Medicare Drug Price Negotiation Program, its process for negotiating with the companies that make the drugs, opportunities for public input and key dates for implementation.
Administration announces first Medicare drug negotiation list
The Department of Health and Human Services announced the first list of Medicare Part D drugs subject to price negotiations, a tenet of the Inflation Reduction Act designed to reduce health care costs.
Drug prices weigh heavily on employers’ minds, according to new study
A new study by Business Group on Health reveals that, amid increases in the percentage of health care dollars spent on pharmacy, 92% of employers are concerned about high-cost drugs in the pipeline, with 91% reporting concern about pharmacy cost trends overall.